Moderna Says COVID-19 Shot 93% Effective 6 Months After Second Dose.

Moderna Says COVID-19 Shot 93% Effective 6 Months After Second Dose

Moderna vaccine shot about 93% effective through six months after the second dose, company said.

Moderna Inc said on Thursday its COVID-19 shot was about 93% effective through six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial.

However, it said it still expects booster shots to be necessary ahead of the winter season as antibody levels are expected to wane. It and rival Pfizer Inc and BioNTech SE have been advocating a third shot to maintain a high level of protection against COVID-19.

During a second-quarter earnings call, Moderna CEO Stephane Bancel said that the company would not produce more than the 800 million to 1 billion doses of the vaccine that it has targeted this year.

"We are now capacity constrained for 2021, and we are not taking any more orders for 2021 delivery," he said.

Moderna shares fell 3.6% to around $403.87 in pre-market trading after closing at $419.05 on Wednesday.

The Moderna data compares favorably to that released by Pfizer and BioNTech last week in which they said their vaccine's efficacy waned around 6% every two months, declining to around 84% six months after the second shot.

Both the Moderna and Pfizer-BioNTech vaccines are based on messenger RNA (mRNA) technology.

"Our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant," Bancel said.

The comment comes as public health officials across the world debate whether additional doses are safe, effective and necessary even as they grapple with the fast-spreading Delta variant of the coronavirus.

Meanwhile, Pfizer is planning to seek authorization for a third shot later this month, and some countries like Israel have begun or plan to start administering a booster shot to older or vulnerable people.

Booster Candidates

Separately, Moderna said its studies of three different booster candidates induced robust antibody responses against variants, including the Gamma, Beta and Delta variants.

It said neutralizing antibody levels following the boost approached those observed after the second shot.

For this year, Moderna has signed vaccine contracts worth $20 billion in sales. It has agreements for $12 billion in 2022, with options for another roughly $8 billion in sales and expects to produce between 2 billion and 3 billion doses next year.

The company, however, has not been able to keep pace with the much larger Pfizer, which expects to manufacture as many as 3 billion doses this year and 2021 sales to top $33.5 billion. Moderna's vaccine was authorized for emergency use in adults in the United States in December and has since been cleared for emergency or conditional use in adults in more than 50 countries.

The company expects to finish its submission for full approval with the U.S. Food and Drug Administration this month.

It posted second-quarter sales of $4.4 billion, slightly above expectations of $4.2 billion drawn from 10 analysts polled by Refinitiv. Its COVID-19 shot is the firm's first authorized product and sales were just $67 million a year earlier.

Moderna earned $2.78 billion, or $6.46 a share, beating quarterly expectations of $5.96 a share.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news
Sky News Breakfast: Major concerns over gas prices

Sky News Breakfast: Major concerns over gas prices

On Sky News Breakfast: - The concerns over gas prices and what happens for customers if smaller firms cannot continue to operate - The Opera star, Carly Paoli on her trip to Barcelona and making a classical album during the pandemic - And the hosp...

A look back on Jimmy Greaves' life and football career.

A look back on Jimmy Greaves' life and football career.

Sky's Enda Brady takes a look at the life and career of late England and Tottenham striker Jimmy Greaves. Greaves passed away today at the age of 81. During an illustrious playing career, the striker scored 382 times in 579 club appearances. Greav...

'You don't behave this way between allies' says French ex-diplomat over new US-UK-Australia deal.

'You don't behave this way between allies' says French ex-diplomat over new US-UK-Australia deal.

French ex-diplomat Gerard Araud suggests a "strategic partnership" between Australia and France has been thrown away after Canberra instead signed a submarine deal with the UK and the US. "We have been undercut in what we considered as a very impo...

Biden fires Down syndrome advocate from disability board.

Biden fires Down syndrome advocate from disability board.

Kurt Kondrich and his daughter discuss his family's efforts to protect people with disabilities despite Biden clearing federal advisory councils of all Trump-appointed members. #FoxNews Subscribe to Fox News! Watch more Fox News Video: Watch Fox N...

1 1073

Tottenham and England legend Jimmy Greaves dead at 81.

Tottenham and England legend Jimmy Greaves dead at 81.

TOTTENHAM and England legend Jimmy Greaves has died aged 81. Tributes have poured in for the Spurs goalscoring hero, who had been battling dementia for a number of years. Read more: Jimmy Greaves was England’s greatest ever goalscorer, a much-love...

German flood victims feel left in the lurch by election campaign - Focus on Europe.

German flood victims feel left in the lurch by election campaign - Focus on Europe.

The destruction caused by Germany's catastrophic flood has made climate change a burning campaign issue. Some flood victims feel abandoned by politics. Subscribe: For more news go to: Follow DW on social media: ►Facebook: ►Twitter: ►Instagram: Für...